Showing results (91-100 of 103) with videos related to
Sort By:
Pageof 11
Frontiers in Endocrinology|February 18, 2026
Defining a serum cortisol cutoff level post-CRH stimulation for diagnosing ACTH deficiency: A retrospective study validated by a nationwide registryTetsushi Izuchi, Shintaro Iwama, Ayana Yamagami, et al.Nature Communications|July 15, 2026
Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltrationYuki Miyai, Yukihiro Shiraki, Ryota Ando, et al.Cancer Immunology Research|February 4, 2026
Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-related HaplotypesTomoko Kobayashi, Shintaro Iwama, Eri Sugiyama, et al.Scientific Reports|October 17, 2022
Differentiation of human induced pluripotent stem cells into hypothalamic vasopressin neurons with minimal exogenous signals and partial conversion to the naive stateHajime Ozaki, Hidetaka Suga, Mayu Sakakibara, et al.Journal of the Endocrine Society|March 31, 2018
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective StudyTomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, et al.The Journal of Clinical Endocrinology and Metabolism|August 2, 2022
Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 BlockadeTomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, et al.International Journal of Cancer|May 17, 2014
Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survivalAlessandra De Remigis, Tanja D de Gruijl, Jennifer N Uram, et al.Journal for Immunotherapy of Cancer|July 2, 2020
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective studyTomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, et al.Cancer Immunology, Immunotherapy : CII|June 4, 2024
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective studyTomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, et al.Endocrinology|January 27, 2022
Functional Lactotrophs in Induced Adenohypophysis Differentiated From Human iPS CellsNatsuki Miyake, Takashi Nagai, Hidetaka Suga, et al.Pageof 11